Chemify – a pioneering company operating its proprietary molecular design, discovery, and chemical manufacturing technology to provide pharmaceutical, biotechnology, and industrial partners with better molecules – recently announced funding of $43 million, including a Series A led by Triatomic Capital, joined by new investors including Hong-Kong based Horizon Ventures, US-based Rocketship Ventures, Possible Ventures, Alix Ventures, Scotland-based Eos, and the UK Government Innovation Accelerators program. Existing investor BlueYard Capital also participated in the round.
Launched in 2019 by CEO Lee Cronin with backing from David Cleevely (co-founder of Abcam), Chemify is based on decades of chemistry research, robotics, AI, and conceptual advancements from Cronin’s Digital Chemistry Laboratory at the University of Glasgow in Scotland. And Professor Cronin’s pioneering research spans the digitization of chemistry including the use of artificial intelligence in chemistry to explore chemical space to access and create the trillions of possible combinations of natural elements.
The company can help reduce the amount of costly and time-consuming experimentation required to discover promising new molecules, speeding up their development as products to underpin advances in medicine, farming, materials science, and green energy. Chemify had spun out from the University of Glasgow in March 2022 and has built a world-class team to commercialize the digitization of chemistry.
The underlying technology was designed and developed by Cronin and his team at the University of Glasgow, based at the Mazumdar-Shaw Advanced Research Centre. With over $30 million invested in the foundational research behind Chemify, the team developed a new digital chemical approach to program chemistry.
Chemify’s vision is to build the infrastructure to digitize chemistry and enable the execution of chemical code for drug discovery, chemical synthesis, and materials discovery. And Chemify is creating a digital chemical future where access to essential molecules, drugs, and new materials that are unimaginable are instantly accessible. Plus, Chemify’s aim is to radically increase the speed of innovation, solve problems, and generate new chemical technologies for the benefit of humanity.
By working closely with select partners with world-class expertise in drug discovery, advanced materials, industrial chemicals, and other specialties, Chemify aims to provide access to its platform and help solve the most complex and impactful chemical design and manufacturing challenges.
KEY QUOTES:
“It has long been our dream to digitize chemistry, and I’m delighted that through this funding, Chemify is building a company that can design, make, and discover complex molecules on demand using digital blueprints faster, more efficiently, and safely than is currently possible. Our mission is to deliver better molecules for pharmaceutical and industrial partners in a fraction of the time and cost currently required.”
— Lee Cronin
“We are excited to be leading the series A in Chemify focussing on delivering digital-chemical solutions to many partners where molecular design and manufacturing is a critical bottleneck.”
— Steve Hochberg from Triatomic Capital
